8 results about "Goserelin" patented technology

This invention belongs to the field of molecular diagnostics, specifically relating to biomarkers for the diagnosis of herpes simplex keratitis (HSK) and their applications. This invention is the first to demonstrate that C1QA and FCERT1G are specific and reliable inflammation-related biomarkers for HSK. Diagnostic and assessment methods based on these biomarkers can provide crucial molecular evidence for the early detection, accurate diagnosis, objective severity grading, and personalized treatment of HSK. Simultaneously, this invention reveals the potential roles of FCERT1G and C1QA in HSK and provides new ideas for targeted therapy of this disease, particularly the application of goserelin as an inflammation modulator, offering a new direction for HSK treatment.

The present application relates to a kind of goserelin microspheres preparation method and its product, comprising the following steps: goserelin raw material solution and degradable polymer solution are mixed, obtain oil phase;Surfactant is mixed with water, obtain water phase;Oil phase is mixed in water phase, form emulsion, stirring solidification, obtain goserelin microspheres;Wherein, the solvent of goserelin raw material solution and degradable polymer solution is each independently co-solvent, the co-solvent is obtained by mixing first solvent and second solvent.The preparation method compared to traditional multiple emulsion method operation is simpler, and the goserelin microspheres prepared simultaneously has higher drug loading and smaller particle size, can realize the injection administration of 7 needle, the surface of microsphere is no hole, burst release is low, can realize the uniform distribution of drug in microsphere, and substantially no acetic acid residue.

The invention relates to the technical field of pharmaceutical preparations, in particular to a goserelin sustained-release microsphere, a goserelin sustained-release microsphere, a preparation method thereof and a sustained-release preparation. The goserelin sustained release microsphere comprises a medicinal active ingredient goserelin and a polymer carrier lactide-glycolide copolymer, wherein the molar ratio of a lactic acid unit to a glycolic acid unit is 75: 25-95: 5. The goserelin sustained release microsphere and the sustained release preparation have the advantages of long drug release period, almost no hysteresis period and sustained and stable release in vivo.

This invention relates to the treatment of breast cancer in a subject, and the subject can be either a male or female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), lerociclib, abemaciclib (Vorzenio), trilaciclib, lerociclib), mTOR inhibitor (everolimus), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3-kinase subunit alpha (PI3Kα)), lapatinib, neratinib (Nerlynx), olaparib (Lynparza) (an inhibitor of the enzyme poly ADP ribose polymerase (PARP)), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; HER2-positive; treating a subject suffering from ER mutant expressing breast cancer and / or treating breast cancer in a subject, by first determining the 18F-16β-fluoro-5α-dihydrotestosterone (18F-DHT) tumor uptake and identifying said subject as having AR-positive breast cancer based on 18F-DHT tumor uptake, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound and a cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor.

The present application provides methods for analyzing and purifying degarelix or a pharmaceutically acceptable salt thereof containing at least one related impurity. Methods for analyzing and purifying degarelix or a pharmaceutically acceptable salt thereof containing Compound A and / or Compound D as impurities are also provided. Further provided are degarelix or a pharmaceutically acceptable salt thereof prepared and / or selected using the disclosed methods.

The invention discloses a stable drug release long-acting goserelin injection type in-situ forming implant, which belongs to the field of biological drug manufacturing, and comprises 20-70 parts by weight of a biodegradable high polymer material, 25-75 parts by weight of a biocompatible organic solvent and 0.2-22 parts by weight of goserelin or a pharmaceutically acceptable salt thereof, the L / G ratio of the biodegradable polymer material PLGA is 50 / 50-95 / 5, and the intrinsic viscosity of the biodegradable polymer material PLGA is 0.08-0.3 dl / g. According to the goserelin injection type in-situ forming implant disclosed by the invention, four key attributes including the intrinsic viscosity of the biodegradable polymer, the glycolic acid aggregation block length, the end capping and the usage amount can be adjusted to be within a proper range in a coordinated manner; the goserelin burst release effect can be remarkably reduced, the delayed drug release platform period can be eliminated, and the treatment requirements of patients can be better met.

The invention relates to a goserelin microneedle implant as well as a preparation method and application thereof, and the preparation method comprises the following steps: mixing a penetration enhancer and normal saline, and then placing the mixture in a mold for drying and curing to form an implant needle tip outer layer; mixing a non-water-soluble polymer material, an organic solvent and a goserelin raw material medicine to obtain a medicine loading liquid, and drying and curing the medicine loading liquid in the implant needle tip outer layer to form a microneedle implant needle tip inner layer; mixing a first water-soluble polymer material with water, and drying and curing in the inner layer of the microneedle implant needle tip to form a microneedle implant needle body; mixing a second water-soluble polymer material with water, placing the mixture on the surface of the needle body of the microneedle implant, drying and curing to form a backing layer, and demolding to obtain the microneedle implant. The drug-loaded microneedle can be completely punctured into the skin through external pressure application, the purpose of slowly releasing drugs in vivo is achieved, the drug action time is prolonged, and the drug administration frequency is reduced.

Described herein are methods of treating hormone receptor positive breast cancer in a patient which include concomitantly administering an initial neoadjuvant or adjuvant IV chemotherapy cycle and an initial dose of a 3.6 mg goserelin acetate implant to the patient, or concomitantly administering an initial dose of a 3.6 mg goserelin acetate implant to the patient with a first of a plurality of long-term IV chemotherapy cycles. After one or more doses of the 3.6 mg goserelin acetate implant, the 3.6 mg goserelin acetate implant is discontinued, and the patient is then administered a 10.8 mg goserelin implant once every 84 to 108 days. Also included are methods of improving patient compliance, increasing duration of treatment, and / or reducing the need for oophorectomy in a patient with hormone receptor positive breast cancer by administering a 3.6 mg goserelin acetate implant to the patient, and upon the patient becoming nonadherent, the 3.6 mg goserelin acetate implant is discontinued, and the patient is then administered a 10.8 mg goserelin implant once every 84 to 108 days.